# Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

> **NCT00267059** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 45 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Leukemia

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00267059
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2012-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267059, "Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00267059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*